Loading...
•
Dec 31, 2022
Nektar Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Nektar Therapeutics reported a decrease in revenue for Q4 2022 compared to Q4 2021, driven by a decrease in non-cash royalty revenue. The company is focused on reducing operating costs to extend its cash runway through at least the middle of 2025. Net loss decreased compared to the same period last year.
Cash and investments in marketable securities were approximately $505.0 million at the end of 2022.
Revenue in the fourth quarter of 2022 was $22.0 million, compared to $25.0 million in the fourth quarter of 2021.
Total operating costs and expenses in the fourth quarter of 2022 were $74.5 million, compared to $137.9 million in the fourth quarter of 2021.
Net loss for the fourth quarter of 2022 was $59.7 million, compared to a net loss of $145.6 million in the fourth quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...